FINWIRES · TerminalLIVE
FINWIRES

研究快讯:吴季文第一季度报告:数字技术进步被利润率暴跌和北美市场拖累所掩盖

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:西联汇款(WU)公布2026年第一季度营收为9.83亿美元(与去年同期持平),超出市场预期2000万美元;调整后每股收益为0.25美元,同比下降39%,低于华尔街预期的0.39美元。由于支出增加和个别项目(包括外汇损失)的影响,营业利润率从18%下降至13%。品牌数字业务表现亮眼,营收增长9%,交易量增长21%,目前占CMT总营收的32%,表明公司在转型方面取得了进展,但不足以抵消传统零售业务的下滑。管理层重申了2026年营收增长5%-8%和调整后每股收益1.75-1.85美元的预期,但前提是预计在第二季度完成对Intermex的收购。受旅行汇款业务增长的推动,消费者服务收入激增24%至1.37亿美元,而消费者汇款业务则下降3%,其中北美地区下降11%。我们认为,西联汇款面临持续的结构性挑战,来自数字化渠道的竞争压力持续挤压传统渠道,尽管数字化发展势头强劲,但利润率扩张仍面临困难。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA